Home » Topics » Regulatory » EMA

EMA
RSS

CHMP adopts positive opinion on Gilead's Genvoya for HIV infection

Sep. 28, 2015

CHMP supports approval of Orkambi and expansion of Kalydeco indications

Sep. 28, 2015

Hemophilia A therapy Elocta recommended for E.U. approval

Sep. 28, 2015

EMA CHMP recommends approval of dabigatran reversal agent idarucizumab

Sep. 28, 2015

EMA CHMP grants accelerated assessment of Janssen's daratumumab for MM

Sep. 25, 2015

EMA recommends approval of mepolizumab for severe refractory eosinophilic asthma

Sep. 25, 2015

EMA committee recommends European approval of Entresto

Sep. 25, 2015

EMA grants orphan drug designation to Stemline's SL-401 for AML

Sep. 14, 2015

European ADAPT SMART initiative launched to improve efficiency in drug development

Sep. 8, 2015

Audentes Therapeutics' AT-001 receives orphan drug designation

Aug. 27, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.